Skip to content

Children and Adolescents With Leukemia, Brain Tumors, and Sarcomas

Social Inequalities in the Participation and Activity in Children and Adolescents With Leukemia, Brain Tumors, and Sarcomas

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04101123
Acronym
SUPATEEN
Enrollment
68
Registered
2019-09-24
Start date
2020-01-01
Completion date
2023-12-31
Last updated
2024-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adolescent Cancer, Brain Tumor, Cancer, Childhood Cancer, Leukemia, Sarcoma

Keywords

Social inequalities, Social dimensions of health, Brain tumors, Leukemia, Sarcomas, Childhood Cancer, Children and adolescents with cancer

Brief summary

Aim of this study is to investigate the influence of social factors on participation and activity among children and adolescents aged 10-18 years with leukemia, brain tumors, and sarcomas. Furthermore personal and treatment-related factors and their impact on participation will be explored

Detailed description

Background: About 2000 children and adolescents under the age of 18 develop cancer each year in Germany. Because of more differentiated diagnostics and standardized treatment protocols, a high survival rate can be reached for many types of the disease. Nevertheless, patients face a number of long-term effects related to the treatment. As a result, physical and psychological consequences have increasingly become the focus of research in recent years. Social dimensions of health have rarely been investigated in pediatric oncology so far. Yet, there are no robust results that allow an estimation of whether and to what extent the disease and treatment impair the participation of children and adolescents and which factors mediate this effect. Social participation is of great importance especially because interactions with peers and experiences in different areas of life are essential for the development of children and adolescents. Methods: Data are collected in a longitudinal, prospective, observational multicenter study. For this purpose, all patients and their parents who are being treated for cancer in one of the participating clinics throughout Germany will be interviewed within the first month after diagnosis (t1), after completion of intensive treatment (t2) and half a year after the end of intensive treatment (t3) using standardized questionnaires. Analysis will be done by descriptive and multivariate methods. Recruitment: Patients will be consecutively recruited in one of the participating clinics throughout Germany.

Interventions

OTHERNon-Interventional

Non-Interventional

Sponsors

Martin-Luther-Universität Halle-Wittenberg
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
10 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* newly diagnosed with confirmed leukemia, brain tumor or sarcoma * age 10-18 years * written informed consent of the patient and of one of the parents if they are under the age of 18

Exclusion criteria

* having a relapse or secondary tumor * insufficient command of German * profound cognitive and physical impairments

Design outcomes

Primary

MeasureTime frameDescription
Social participation and activityWithin the first month after diagnosis until half a year after intensive treatmentThe Child and Adolescent Scale of Participation, CASP
Level of quality of lifeWithin the first month after diagnosis until half a year after intensive treatmentQuestionnaire to assess Health Related Quality of Life in chronically ill Children and Adolescents, KINDL Subscales: physical well-being, emotional well-being, self-esteem, family, friends, school, and a total score Values: range from 0 to 100 (higher values represent better quality of life)

Secondary

MeasureTime frameDescription
FatigueWithin the first month after diagnosis until half a year after intensive treatmentSubscale Fatigue from the Questionnaire to assess Quality of Life of Cancer Patients developed by the European Organisation for Research and Treatment of Cancer, EORTC QLQ-C30 Values: range from 0 to 100 (higher values represent higher symptoms of fatigue)
Self-conceptWithin the first month after diagnosis until half a year after intensive treatmentSelf-Description Questionnaire, SDQ
Social supportWithin the first month after diagnosis until half a year after intensive treatmentSocial Support Scale, SSS Values: total score with a range 8-40 (higher values represent higher support)
Illness perceptionWithin the first month after diagnosis until half a year after intensive treatmentIllness Perception Questionnaire, IPQ
Self-efficacyWithin the first month after diagnosis until half a year after intensive treatmentGeneral Self-Efficacy Scale; SWE
OptimismWithin the first month after diagnosis until half a year after intensive treatmentSubscale from The Bern Subjective Well-Being Questionnaire for Adolescents, BFW
Psychosocial problems and strengthsWithin the first month after diagnosis until half a year after intensive treatmentStrengths and Difficulties Questionnaire, SDQ Subscales: emotional problems, conduct problems, peer problems, hyperactivity, and prosocial behavior Values: each scale has a range 0-10 (higher values represent higher problems except prosocial behavior)
Sense of coherenceWithin the first month after diagnosis until half a year after intensive treatmentChildren Sense of Coherence Scale, C-SOC
CopingWithin the first month after diagnosis until half a year after intensive treatmentCoping Questionnaire for Children and Adolescents, CODI
Mental healthWithin the first month after diagnosis until half a year after intensive treatmentChildren's Depression Screener, Child-S
AutonomyWithin the first month after diagnosis until half a year after intensive treatmentSubscale from The Kidscreen Questionnaire
Evaluation of the treatmentEnd of intensive treatmentQuestionnaire to assess the Satisfaction with the Treatment, FBB Subscales: success of treatment (range 0-20), relationship to medical team (range 0-28), treatment conditions (range 0-24), and a total score (range 0-72) Values: higher values represent better evaluation

Other

MeasureTime frameDescription
Familial burdenEnd of intensive treatment until half a year after intensive treatmentImpact on Family Scale in Families with Children with Disabilities, FaBel (parental questionnaire)
Family resourcesWithin the first month after diagnosis and half a year after intensive treatmentFamily Environment Scale, FES (parental questionnaire)
Satisfaction with lifeWithin the first month after diagnosis until half a year after intensive treatmentThe Satisfaction With Life Scale, SWL
Doctor-parent relationshipEnd of intensive treatmentPatient Reactions Assessment, PRA-D
Level of quality of lifeWithin the first month after diagnosis until half a year after intensive treatmentThe Short Form Health Survey, SF-12
Sense of coherenceWithin the first month after diagnosis until half a year after intensive treatmentSense of Coherence Scale - Leipziger Short Form, SOC-L9
Mental healthWithin the first month after diagnosis until half a year after intensive treatmentHospital Anxiety and Depression Scale, HADS
Psychosocial needsWithin the first month after diagnosis until the end of intensive treatmentShort-Form Supportive Care Needs Survey Questionnaire, SCNS-SF34 (parental questionnaire)
Evaluation of the treatmentEnd of intensive treatmentQuestionnaire to assess the Satisfaction with the Treatment, FBB
Parental coping with chronic childhood diseaseWithin the first month after diagnosis until half a year after intensive treatmentCoping Health Inventory for Parents, CHIP (parental questionnaire)

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026